I believe that the worst is now behind us . We have had a very challenging few years but in the last couple of years , several corrections have been made in regulations
I believe that the worst is now behind us . We have had a very challenging few years but in the last couple of years , several corrections have been made in regulations
also see the regulators seek feedback periodically on the new guidelines and procedures which indicates that they are very open to incorporating stakeholder feedback and making their processes even more robust . What we now need is an investment in proper governance to ensure that the guidelines are implemented and governed well .
On approval timelines , while they have reduced significantly from a few years ago , if we want to be competitively positioned with other countries , we need to bring down approval timeline approvals further from the current six to seven months to three months . This would then be another compelling reason for sponsors to conduct clinical trials in India .
Hopefully , there will be greater understanding of the role and value of clinical research . I am optimistic that Make in India for clinical research will be a reality with more innovation and R & D taking place in our country .
Based out of Bangalore office , Naz is responsible for providing vision , strategic business and technology direction , and operational capabilities to support the company ’ s growth across Asia . Bringing 25 years of experience in international business systems , technology process re-engineering and consulting , Naz has been a key leader within multiple industries including pharmaceuticals , manufacturing , utilities and various other sectors .
MR NAZ HAJI IS THE SENIOR VICE PRESIDENT AND MANAGING DIRECTOR OF QUINTILESIMS .
BIOVOICENEWS . COM 39